Patch Test Reactions Associated With Topical Medications : A Retrospective Analysis of the North American Contact Dermatitis Group Data (2001-2018)
Copyright © 2021 American Contact Dermatitis Society. All Rights Reserved..
BACKGROUND/OBJECTIVES: Topical medications may lead to allergic contact dermatitis. This study characterized positive patch test reactions associated with medications in patients evaluated by the North American Contact Dermatitis Group (NACDG).
METHODS: This study is a retrospective analysis of the NACDG data (2001-2018). Patients with at least 1 positive patch test reaction associated with a medication source were included. Allergens, reaction characteristics, clinical relevance, and source details were tabulated.
RESULTS: Of 43,722 patients, 6374 (14.6%) had positive allergic patch test reactions associated with 1 or more topical medication sources. Patients with versus without allergic reactions to medications were more likely to be older than 40 years (P < 0.0001) and/or have primary sites of dermatitis on the legs, anal/genital region, or trunk (P < 0.0001). There were 8787 reactions to NACDG allergens; the most common were neomycin (29.4%), bacitracin (29.1%), propylene glycol 100% (10.6%), tixocortol-17-pivalate (10.0%), lidocaine (7.9%), budesonide (4.9%), and dibucaine (4.4%). Propylene glycol 100% was the most common inactive ingredient (10.6%). Current relevance was present in 61.0%. A total of 6.5% of the individuals with medication allergy would have had 1 or more positive patch test reactions missed if only tested to the NACDG screening series.
CONCLUSIONS: Positive patch test reactions associated with topical medications were common (14.6%), and most were clinically relevant. Patients with topical medication allergy were twice as likely to have anal/genital involvement. Active ingredients, especially neomycin, bacitracin, and tixocortol-17-pivalate, were frequent culprits.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Dermatitis : contact, atopic, occupational, drug - 33(2022), 2 vom: 01. März, Seite 144-154 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Warshaw, Erin M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 21.03.2022 Date Revised 16.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/DER.0000000000000777 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329494023 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329494023 | ||
| 003 | DE-627 | ||
| 005 | 20231225205234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/DER.0000000000000777 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM329494023 | ||
| 035 | |a (NLM)34405832 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Warshaw, Erin M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patch Test Reactions Associated With Topical Medications |b A Retrospective Analysis of the North American Contact Dermatitis Group Data (2001-2018) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2022 | ||
| 500 | |a Date Revised 16.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 American Contact Dermatitis Society. All Rights Reserved. | ||
| 520 | |a BACKGROUND/OBJECTIVES: Topical medications may lead to allergic contact dermatitis. This study characterized positive patch test reactions associated with medications in patients evaluated by the North American Contact Dermatitis Group (NACDG) | ||
| 520 | |a METHODS: This study is a retrospective analysis of the NACDG data (2001-2018). Patients with at least 1 positive patch test reaction associated with a medication source were included. Allergens, reaction characteristics, clinical relevance, and source details were tabulated | ||
| 520 | |a RESULTS: Of 43,722 patients, 6374 (14.6%) had positive allergic patch test reactions associated with 1 or more topical medication sources. Patients with versus without allergic reactions to medications were more likely to be older than 40 years (P < 0.0001) and/or have primary sites of dermatitis on the legs, anal/genital region, or trunk (P < 0.0001). There were 8787 reactions to NACDG allergens; the most common were neomycin (29.4%), bacitracin (29.1%), propylene glycol 100% (10.6%), tixocortol-17-pivalate (10.0%), lidocaine (7.9%), budesonide (4.9%), and dibucaine (4.4%). Propylene glycol 100% was the most common inactive ingredient (10.6%). Current relevance was present in 61.0%. A total of 6.5% of the individuals with medication allergy would have had 1 or more positive patch test reactions missed if only tested to the NACDG screening series | ||
| 520 | |a CONCLUSIONS: Positive patch test reactions associated with topical medications were common (14.6%), and most were clinically relevant. Patients with topical medication allergy were twice as likely to have anal/genital involvement. Active ingredients, especially neomycin, bacitracin, and tixocortol-17-pivalate, were frequent culprits | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Allergens |2 NLM | |
| 700 | 1 | |a Shaver, Rob L |e verfasserin |4 aut | |
| 700 | 1 | |a DeKoven, Joel G |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, James S |e verfasserin |4 aut | |
| 700 | 1 | |a Atwater, Amber R |e verfasserin |4 aut | |
| 700 | 1 | |a Fransway, Anthony F |e verfasserin |4 aut | |
| 700 | 1 | |a Maibach, Howard I |e verfasserin |4 aut | |
| 700 | 1 | |a Belsito, Donald V |e verfasserin |4 aut | |
| 700 | 1 | |a Silverberg, Jonathan I |e verfasserin |4 aut | |
| 700 | 1 | |a Houle, Marie-Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Reeder, Margo J |e verfasserin |4 aut | |
| 700 | 1 | |a Zug, Kathryn A |e verfasserin |4 aut | |
| 700 | 1 | |a Fowler, Joseph F |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Sasseville, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Pratt, Melanie D |e verfasserin |4 aut | |
| 700 | 1 | |a Dunnick, Cory A |e verfasserin |4 aut | |
| 700 | 1 | |a DeLeo, Vincent A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatitis : contact, atopic, occupational, drug |d 2004 |g 33(2022), 2 vom: 01. März, Seite 144-154 |w (DE-627)NLM151459118 |x 2162-5220 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:2 |g day:01 |g month:03 |g pages:144-154 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/DER.0000000000000777 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2022 |e 2 |b 01 |c 03 |h 144-154 | ||